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ABSTRACT
Targeted differentiation of human induced pluripo-
tent stem cells (hiPSCs) using only chemicals would
have value-added clinical potential in the regenera-
tion of complex cell types including cardiomyocytes.
Despite the availability of several chemical inhibitors
targeting proteins involved in signaling pathways, no
bioactive synthetic DNA-binding inhibitors, targeting
key cell fate-controlling genes such as SOX2, are
yet available. Here, we demonstrate a novel DNA-
based chemical approach to guide the differentia-
tion of hiPSCs using pyrrole–imidazole polyamides
(PIPs), which are sequence-selective DNA-binding
synthetic molecules. Harnessing knowledge about
key transcriptional changes during the induction
of cardiomyocyte, we developed a DNA-binding in-
hibitor termed PIP-S2, targeting the 5′-CTTTGTT-3′
and demonstrated that inhibition of SOX2–DNA in-
teraction by PIP-S2 triggers the mesoderm induc-
tion in hiPSCs. Genome-wide gene expression anal-
yses revealed that PIP-S2 induced mesoderm by tar-
geted alterations in SOX2-associated gene regula-
tory networks. Also, employment of PIP-S2 along
with a Wnt/-catenin inhibitor successfully gen-
erated spontaneously contracting cardiomyocytes,
validating our concept that DNA-binding inhibitors
could drive the directed differentiation of hiPSCs. Be-
cause PIPs can be fine-tuned to target specific DNA
sequences, our DNA-based approach could be ex-
panded to target and regulate key transcription fac-
tors specifically associated with desired cell types.
INTRODUCTION
Human induced pluripotent stem cells (human iPSCs; hiP-
SCs) are a promising resource for regenerative medicine,
drug discovery, and disease modeling, because they can
differentiate into all three germ layers and avoid the eth-
ical issues associated with the use of human embryonic
stem cells (ESCs). Directed differentiation of hiPSCs has
been achieved by modulating signaling pathways with var-
ious growth factors and cytokines to mimic natural or-
gan development (1,2). Differentiation of hiPSCs using
small molecule inhibitors has been favored because they are
transgene-free, cost-effective and are readily applicable (3–
6). In principle, these syntheticmoleculesmodulate cell fate-
regulating signaling pathways by binding to specific pro-
teins and inhibiting specific receptor–ligand interactions or
enzymatic activity. However, these compounds might target
additional signaling components, and the requirement of
multiple modulators for directed differentiation also com-
plicates the issues.
Since the transcriptional network eventually dictates cell
fate specification, the direct regulation of specific gene ex-
pression could be an effective strategy to control the dif-
ferentiation of hiPSCs. High-throughput sequencing stud-
ies have been revealing several cell fate-modulating tran-
scription factors (TFs) and their key regulatory motifs (7–
9). Until now, strategies to modulate key TFs still largely
rely on exogenous genetic materials and hence are not fa-
vored for clinical use. Consequently, there is a need to de-
velop convenient-to-use DNA-binding inhibitors with de-
fined compositions for cell fate-regulating TFs. For this pur-
pose, we explored whether we could harness the chemical
biology of nucleic acids to construct a DNA-binding in-
hibitor for a TF named SOX2, known as a negative reg-
ulator of mesoderm induction of hiPSCs (10,11). Hairpin
pyrrole–imidazole polyamides (PIPs) are a class of synthetic
molecules composed of N-methylpyrrole units (Py) and N-
methylimidazole units (Im) (12). PIPs can bind to the DNA
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minor groove in a sequence-selective manner (anti-parallel
Py/Py pairs recognize A•T or T•A base pairs and Im/Py
pairs recognize G•C base pairs) (13) and their selectivity
and affinity are similar to those of naturally occurring TFs
(14). PIPs have been reported to repress transcription by
inhibiting DNA–TF interactions in sequence-specific man-
ners (15–19). PIPs have moderate cell permeability and nu-
clear localizing properties without the need for delivery
reagents (19,20). Moreover, PIPs can be generated readily
using automated solid phase peptide synthesizers.
Until now, PIPs have not been shown to differentiate
hiPSCs, but here we demonstrate that a PIP targeting the
consensus-binding motif of the SOX2 TF could signifi-
cantly guide the differentiation of hiPSCs into mesoderm.
Cardiomyocytes were chosen as the target cell type because
the differentiation progression and regulatory mechanisms
leading to the generation of cardiomyocytes are well studied
(21,22). PIP-induced mesoderm generated spontaneously
contracting cardiomyocytes upon treatment with a Wnt/-
catenin signaling inhibitor. This study serves as the first
proof-of-concept study validating the application of a syn-




All PIPs used in this study were synthesized as described
previously (18,23). Briefly, Fmoc solid-phase synthesis of
designed PIP structures was performed on a PSSM-8 (Shi-
madzu), then cleavage was carried out with 1 ml of 3,3′-
diamino-N-methyldipropylamine (Dp) for 3 h at 45◦C. The
resulting crude PIPs were purified by flash column chro-
matography. The purified PIPs were then characterized by
HPLC and MALDI-TOF/MS. Further detailed informa-
tion about PIP synthesis is provided in supplementary in-
formation.
T m assay
PIPs (12.5 M) were mixed with DNA duplex (2.5 M) in
100 l mixture containing sodium cacodylate (10 mM, pH
7.0) and sodium chloride (10 mM) containing 2.5% (v/v) of
dimethylformamide (DMF). The sequence of DNA duplex
used is 5′-GGCACTTTGTTATGCGG-3′, where the un-
derlined region indicates binding site of SOX2. Annealing
was performed by decreasing the temperature of the mix-
ture from 90◦C to 25◦C (−1◦C/min). DNAmelting was as-
sessed by measuring the absorbance of mixture at  = 260
nm from 25◦C to 90◦C (1◦C/min, 1 measurement/◦C) on
V-650 UV-VIS spectrometer (Jasco).
Electrophoretic mobility shift assay (EMSA)
Recombinant protein of DNA-binding domain of SOX2
(highmobility group;HMG)was prepared as previously de-
scribed (24,25). PIPs were incubated with the DNA duplex
(5′–GGCACTTTGTTATGCGG–3′, 30 pmol) in 9 l mix-
ture containing sodium cacodylate (13.3 mM, pH 7.0) and
sodium chloride (13.3 mM) for at least 1 h at room tem-
perature. Human recombinant SOX2 (90 pmol) was then
added to attain 12 l of total volume and the mixture was
incubated for 1 h at room temperature. 2.5 l of loading
dye (#B7025S; New England Biolabs) was added and 10
l was loaded to 20% polyacrylamide gel (acrylamide:bis-
acrylamide = 29:1, 1× TBE). The gel was run at 120 V
for first 30 min, followed by 180 V for 150 min. DNA was
stained with ethidium bromide and visualized. The band
intensities of SOX2–DNA complex were determined using
ImageJ software (https://imagej.nih.gov/ij/).
Culture and maintenance of hiPSCs
All cell cultures were performed at 37◦C with 5% CO2.
201B7 iPS cell line was provided by the RIKEN BRC
through the National Bio-Resource Project of the MEXT,
Japan. After being cultured in SNL feeder/20% Knock-
out Serum Replacement (KSR) condition, hiPSCs were
transferred and routinely maintained on Matrigel (hESC-
qualified; Corning) with mTeSR1 (Stemcell Technologies)
medium supplemented with 0.5× penicillin/streptomycin
(Nacalai Tesque). Cells were passaged using the dissocia-
tion reagent containing 0.5 mM ethlendiaminetetraacetic
acid disodium salt (EDTA•2Na) in Dulbecco’s phosphate-
buffered saline without calcium/magnesium (D-PBS(−);
Nacalai Tesque). 2.5MofRock inhibitor Y-27632 (Wako)
was supplemented to the medium for one day after passage.
Mesoderm induction
On day −2, hiPSCs of passage 50–90 were detached with
0.5 mMEDTA•2Na/D-PBS(−) to attain small cell clumps.
Cells were suspended in mTeSR1 that is supplemented with
0.5× penicillin/streptomycin and 2.5MY-27632 and then
were seeded onto Matrigel-coated culture dishes/plates
(typically 0.2–1.0 × 104 cells/cm2). On day 0 the medium
was replacedwith differentiationmedium (DM) constituted
with Advanced RPMI 1640 medium (Thermo Fisher Scien-
tific) and 0.2% fetal bovine serum (FBS; Sigma) and 1× L-
glutamine (Wako) with/without 2 M PIP. 0.1% dimethyl
sulfoxide (DMSO) was used as a vehicle. On day 1, the
medium was exchanged with the same composition. Typi-
callymesoderm-like cells emerged on day 4 or 5. To evaluate
the induction efficiency byPIP-S2, the combination ofPIP-
S2 and Matrigel overlay was used where the chilled DM
supplemented with Matrigel (one aliquot in 25 ml medium
according to the product information) andPIP-S2was used
with medium exchange on day 1.
For the CHIR99021-mediated mesoderm induction, cells
were seeded with the same protocol and incubated with
daily medium exchange until the cells become 30% conflu-
ent. Then themediumwas replaced withDM supplemented
with 2 M of CHIR99021 (Wako) and the cultured cells
were incubated for 2 days (5).
Cardiomyocytes generation
After performing mesoderm induction as described above,
the medium was replaced with DM supplemented with 5
M IWP-2 (Wako). Afterward, on day 7 the medium was
replaced with DM without any additive and exchanged
once in 2–4 days. For immunocytochemistry analysis of
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the individual cardiomyocytes, the spontaneously contract-
ing cluster was picked up and dissociated by TrypLE Se-
lect (Thermo Fisher Scientific). The cells were re-seeded
onto a cover glass (Matsunami Glass) coated with Matrigel
(hESC-qualified; Corning).
RT-qPCR
Total RNAwas extracted by RNeasyMini Kit (Qiagen) ac-
cording to the manufacturer’s manual. 100–500 ng of to-
tal RNA was reverse transcribed into cDNA by ReverTra
Ace qPCR RTMaster Mix with gDNA Remover (Toyobo)
and qPCR was performed using THUNDERBIRD SYBR
qPCR Mix (Toyobo) in LightCycler 480 (Roche Diagnos-
ticsGmbH). Cp value was determined by the second deriva-
tive maximum method and relative RNA amount was cal-
culated by the Cp method. P-value was calculated by
one-sample t-test using data from independent experiments.
The sequences of the primers are listed in Supplementary
Table S1.
Immunocytochemistry
For immunocytochemical analysis, except for primary an-
tibody incubation, all the following incubations were per-
formed at room temperature. Cells were fixed with 4%
paraformaldehyde for 30 min, permeabilized with 0.5% Tri-
ton X-100 for 10 min and blocked with 5% bovine albumin
serum (BSA; Nacalai Tesque) for 30 min. Afterward, the
cells were incubated with primary antibody in 1% BSA for
overnight at 4◦C and incubated with secondary antibody
in 1% BSA for 50 min. Nuclei were stained with 1 g/ml
Hoechst 33342. Antibodies used are listed in Supplemen-
tary Table S2.
Flow cytometry
Cells were detached by treating TrypLE Select (Thermo
Fisher Scientific) for 7–10 min at 37◦C, followed by chemi-
cal fixation with 4% paraformaldehyde for 10 min at 37◦C
and permeabilization with 90%methanol for 30 min at 4◦C.
Then, the cells were incubated with primary antibody for
60 min at room temperature followed by incubation with
secondary antibody for 30 min at room temperature. FACS
Aria II (BDBioscience) was used to detect fluorescence. An-
tibodies used are listed in Supplementary Table S2.
Microarray
After extracting total RNA as above, the quality of RNA
was assessed with Bioanalyzer (Agilent Technologies) us-
ing Agilent RNA 6000 Pico Kit (Agilent Technologies). Bi-
otinylated fragmented cDNA was prepared by GeneChip
WT PLUSReagent Kit (Affymetrix) and hybridized to Hu-
man Gene 2.1 ST Array Strip (Affymetrix) using GeneChip
Hybridization, Wash, and Stain Kit (Affymetrix). Flu-
idics and scanning were performed in GeneAtlas Sys-
tem (Affymetrix) using GeneChip Hybridization, Wash,
and Stain Kit (Affymetrix) and the obtained raw data set
was normalized and summarized by Expression Console
(Affymetrix). Ingenuity Pathway Analysis (IPA; Qiagen)
was used for upstream analysis.
Z-score for gene A in sample i (Z(A, i)) was calculated
by the following formula:
Z(A, i ) = x(A, i ) − μ(A)
σ (A)
where x(A, i) is the normalized signal intensity of gene A
in sample i, μ(A) is the mean of x(A), σ (A) is the standard
deviation of x(A).
RESULTS
Design and synthesis of a DNA-binding inhibitor of SOX2
The target selection of our proof-of-concept study to con-
struct the DNA-binding inhibitor arose conceptually from
the well-known mechanism of cardiomyocyte differentia-
tion. Differentiation of hiPSCs into cardiomyocytes com-
prises of two major stages: mesoderm induction and car-
diomyocyte specification (21,22). The first stage of meso-
derm induction is typically achieved by activating the
Wnt/-catenin and TGF- signaling pathways (4,26,27).
The repression of SOX2 downstream of these pathways is
a critical event in this stage (22). SOX2 is a key TF that
is highly expressed in pluripotent stem cells, and is one
of the essential components for generation of both mouse
and human iPSCs (28,29). In hiPSCs, SOX2 is responsible
for maintaining pluripotency and neuroectodermal lineage
specification and prevents differentiation into mesodermal
and endodermal lineages (30). Consistent with this idea,
knockdown of SOX2 is known to induce meso/endoderm
induction from hiPSCs (10,22). In addition, it has been also
demonstrated that the inhibiting transcriptional activity of
SOX2 in mESCs enhances the appearance of early neu-
ronal and cardiac progenitors (31). Because short interfer-
ing (si)RNA-mediated gene knockdown involves problem-
atic handling and stability issues, there is a need to develop
DNA-binding chemical inhibitors.
Based on these facts, we designed two hairpin DNA-
binding PIPs (PIP-S1 and PIP-S2) to inhibit SOX2
function by occupying its target DNA sequence (5′-
CTTTGTT-3′) for mesoderm induction (Figure 1) (32).
PIP-S1 has a typical 4–4 ring architecture targeting the
5′-CTTTGTT-3′ sequence. PIP-S2 has an extended archi-
tecture with increased recognition specificity to target 5′-
CTTTGTT-3′. The anticipated binding mode of the two
PIPs is shown in Figure 1B. To confirm the binding,
we used a template DNA with the following sequence
5′-GGCACTTTGTTATGCGG-3′. A melting temperature
(Tm) assay (33) confirmed the binding of both the PIPs to
target DNA as Tm shifts of 11.8◦C and 18.6◦C were ob-
served forPIP-S1 andPIP-S2, respectively (Figure 2A). An
electrophoretic mobility shift assay (EMSA) carried out to
study SOX2–DNA interaction showed that increasing con-
centrations of both the PIPs decreased the amount of the
SOX2–DNA complex (Figure 2B and C). Following this
concept, PIP-S2 inhibited SOX2 binding more effectively
than did PIP-S1. At the same concentration as SOX2 (3
eq. against DNA), PIP-S2 reduced the band intensity of
the SOX2–DNA complex by >70% (Figure 2B and C, lane
15), confirming its superior binding affinity to SOX2. PIP-
S1 showed the plateau in its effect at higher concentrations
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Figure 1. The design of pyrrole–imidazole polyamides (PIPs) targeting the
binding DNA sequence of SOX2. (A) Chemical structure of hairpin PIPs,
namely PIP-S1 and PIP-S2. (B) Targeting mode of designed PIPs to the
consensus sequence of a SOX2 binding site (5′–CTTTGTT–3′).
(Figure 2B and C, lanes 7–9). One possible reason for this
plateau could be the formation of aggregates at the higher
concentration of PIP-S1 (34).
PIP-S2 induces mesoderm from hiPSCs
To evaluate the bioactivity of the designed PIPs, after
initial optimization studies, 2 M of PIP-S1 and PIP-
S2 were added to the RPMI 1640-based differentiation
medium used for culturing hiPSCs (Supplementary Fig-
ure S1). Immunocytochemical studies for the mesoderm
marker BRACHYURY (T) revealed that PIP-S1-treated
hiPSCs had a background level of BRACHYURY expres-
sion similar to that observed with vehicle-treated hiPSCs.
On the other hand, PIP-S2 caused remarkable upregula-
tion of BRACHYURY protein expression in hiPSCs (Fig-
ure 3A, Panel BRACHYURY). Because SOX2 expression
is known to be repressed immediately following mesoderm
induction (22), the effects of these PIPs on the expression
of SOX2 were evaluated. As we expected, BRACHYURY-
positive cells induced by PIP-S2 suppressed the level of the
SOX2 protein (Figure 3A, Panel SOX2). Consistently, ex-
pression of SOX2wasmaintained in hiPSCs treatedwith ve-
hicle andPIP-S1 (Figure 3A, Panel SOX2). Quantitative re-
verse transcription polymerase chain reaction (RT–qPCR)
analysis further validated that PIP-S2 treatment triggered
significant induction (P< 0.001) of BRACHYURY (T) and
significant repression (P < 0.05) of SOX2 gene expression
(Figure 3B, Bars T and SOX2). It is important to note here
that the different bioactivity between PIP-S1 and PIP-S2
is consistent with the binding data attained with the in vitro
Tm assays and EMSA discussed above. Therefore, it is ratio-
nal to propose thatmesoderm induction is caused by the rel-
atively higher binding affinity of PIP-S2 than that of PIP-
S1 toward the target sequence. To further evaluate the ef-
fect of PIP-S2 on transcription programs associated with
mesoderm specification, endogenous expression of other
mesoderm marker genes was evaluated. Again, PIP-S2 sig-
nificantly (P < 0.05) activated mesoderm/mesendoderm-
associated marker genes (GSC, MIXL1, MSX1) and car-
diac mesoderm-relatedmarker genes (MESP1 andGATA4)
(Figure 3B). PIP-S2 also triggered significant (P < 0.05)
upregulation of genes related to Wnt/-catenin (WNT3A
and WNT8A) and TGF (BMP4, NODAL and LEFTY1)
signaling pathways, which are essential for the induction
of mesoderm (Figure 3B) (26). Thus, we successfully devel-
oped PIP-S2 as a DNA-binding inhibitor of SOX2 capable
of significantly inducing marker genes associated with car-
diac mesoderm specification in hiPSCs.
Genome-wide gene expression analysis validates sequence-
specific inhibition of SOX2 and its function as the mechanism
behind the PIP-S2-mediated induction of mesoderm
To investigate the possible mechanism behind the induc-
tion of cardiac mesoderm by our DNA-binding inhibitor,
we performed genome-wide gene expression studies of
the PIP-S2-treated hiPSCs and compared their expression
profile with that observed in vehicle-treated hiPSCs. Up-
stream analysis of the differentially expressed genes at day
3 (PIP-S2 vs vehicle) predicted SOX2 as the most signif-
icant upstream regulator (P = 1.38 × 10−8; Figure 4A)
and suggested the inhibition of SOX2 and not its activa-
tion (Figure 4A). However, the Z-score of -1.18 was not
significant enough (>2 or <−2 is significant). To com-
pare the bioactivity of PIP-S2 and its siRNA, we extracted
the expression profile of a series of genes reported to be
activated/repressed by SOX2 knockdown (22). For most
genes activated by SOX2 knockdown, we observed the up-
regulation by PIP-S2 (27, 27, 32 out of 36 genes on day 4, 5,
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Figure 2. PIP-S2 is a potent inhibitor of SOX2–DNA interaction. (A) Tm assay of PIPs. Means ± standard deviations from three measurements are
indicated. (B) EMSA of PIPs. DNA (2.5 M) with increasing concentrations of each PIP was incubated with 7.5 M of SOX2 (three times the amount
of DNA) for 1 h. DNA and the SOX2–DNA complex were separated by polyacrylamide gel electrophoresis and stained with ethidium bromide. (C)
Inhibition of SOX2–DNA interaction by PIPs. The band intensities of SOX2–DNA complex in the Figure 2B were determined using ImageJ software
(https://imagej.nih.gov/ij/). The intensity in lane 2 was set to 1.0.
6, respectively; Figure 4B, Supplementary Table S3). On the
other hand, the genes downregulated by SOX2 knockdown
showed lesser correlation than those by PIP-S2 (17, 15, 11
out of 26 genes on day 4, 5, 6, respectively; Supplementary
Figure S2, Supplementary Table S4). The reason could be
attributed to the intrinsic smaller expression changes for
SOX2 knockdown-repressing genes (Supplementary Table
S4). Analysis of overlapping genes in the top 100 regulated
transcripts also highlighted the significant correlation for
the upregulated genes between PIP-S2 and SOX2 knock-
down, but not for the downregulated genes (Supplementary
Figure S3). Overall, the generated heat map inferred that
the expression pattern observed with PIP-S2 treatment was
roughly consistent with the effect of siRNA-mediated SOX2
knockdown, especially in the upregulated genes. Thus, these
genome-wide gene analyses implied the inhibition of SOX2
by PIP-S2 as a plausible mechanism behind the induction
of mesoderm (Figure 4C), thereby validating the efficacy of
our strategy.
To confirm that the effect of PIP-S2 is sequence-specific,
we designed and synthesized another PIP (PIP-C) of the
same length but with a different chemical structure as a
control (Supplementary Figure S4). A melting temperature
(Tm) assay for PIP-C showed a Tm shift of 13.1◦C, suggest-
ing the lower affinity to the template DNA than that to-
wards PIP-S2 (Supplementary Figure S5). EMSA showed
that the SOX2-inhibiting ability of the PIP-C was worse
than that of PIP-S2 (Supplementary Figure S6). Consis-
tent with the pattern observed with in vitro binding stud-
ies, PIP-C also could not repress SOX2 gene expression
nor activate mesoderm-associated T expression (Supple-
mentaryFigure S7).Hence, sequence-specific recognition of
5′–CTTTGTT–3′ by PIP-S2 appears to be essential for the
bioactivity.
PIP-S2-induced cardiac mesoderm further differentiates into
functional cardiomyocytes upon supplementation with a
Wnt/-catenin signaling inhibitor
Because targeted differentiation using chemicals alone is
believed to have clinical benefits, we screened for the opti-
mal small molecule that might complement the bioactivity
of PIP-S2 and differentiate the PIP-S2-induced mesoderm
into functional cardiomyocytes. Cardiac specification, the
second stage followed by mesoderm induction, is known to
be driven upon the inhibition of Wnt/-catenin signaling
(4). Hence, after incubating 201B7 hiPSCs with PIP-S2 for
5 days, the cells were exposed to Wnt/-catenin signaling
inhibitor IWP-2 for 2more days (days 5–7). After this short-
term exposure to IWP-2, the cells were further incubated in
the differentiation medium with exchange every 2–4 days
(Figure 5A). Around day 12, several cells began to sponta-
neously contract (Supplementary Movie S1 and S2), indi-
cating the generation of functional cardiomyocytes. Count-
ing the generated cell clusters corroborated that sequen-
tial treatment with PIP-S2 and IWP-2 successfully gener-
ated several pulsating clusters, whereas the treatment of hiP-
SCs without PIP-S2 did not generate any pulsating clus-
ters (Figure 5B). Immunocytochemistry also confirmed the
expression of the main marker proteins TNNT2, NKX2–
5, -actinin and MLC2A to validate the typical character-
istics of functional cardiomyocytes (Figure 5C). Further-
more, the expression patterns of TNNT2 and -actinin in-
dicated the presence of sarcomeres, the fundamental struc-
tures of myocytes. These independent lines of evidence im-
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Figure 3. PIP-S2 induces the mesodermal lineage in hiPSCs. (A) Immunohistochemistry of the mesoderm marker BRACHYURY and
pluripotency/ectoderm marker SOX2 in PIP-treated 201B7-hiPSCs on day 5. Scale bars; 100 m. (B) RT-qPCR analysis of 201B7-hiPSCs treated with
PIP-S2 for 5 days. Relative RNA amount (vehicle on day 5 vs PIP-S2 on day 5) is shown in logarithmic scale. Means ± the standard errors of the mean
(SEM) from three independent experiments are indicated. *P < 0.05, **P < 0.01, ***P < 0.001.
ply that the cardiomyocytes generated by PIP-S2/IWP-2
have typical structural and functional characteristics of car-
diomyocytes.
Matrigel overlay approach is known to promote
epithelial–mesenchymal transition (EMT) in the meso-
derm induction stage (35). Accordingly, our optimization
studies also showed that Matrigel overlay could enhance
PIP-S2-mediated mesoderm induction (data not shown).
The efficiency of mesoderm induction was then evaluated
with this optimized protocol along with the standard
protocol using a GSK3 inhibitor CHIR99021 (4,5). Flow
cytometry analysis showed that PIP-S2 produced 44.7%
of SOX2 (−)/BRACHYURY (+) population after 5 days
treatment which was ∼47% lower than the population at-
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Figure 4. PIP-S2 induces mesoderm via the inhibition of SOX2. (A) Upstream regulator analysis of >2 fold up-/downregulated genes in PIP-S2-treated
201B7-hiPSCs compared with vehicle-treated 201B7 on day 3. Rank 1–5 upstream regulators based on P values are shown. (B) Heat map of genes upreg-
ulated by the SOX2 knockdown in hESCs. Microarray studies were performed for the PIP-S2- or vehicle-treated cells on days 3, 4 and 5. Values represent
the differences in Z-scores between the expression level in PIP-S2-treated hiPSCs and that in vehicle-treated cells. (C) Schematic illustration of the plausible
mechanism for mesoderm induction by PIP-S2.
tained with CHIR99021 for 2 days (Supplementary Figure
S8). However, RT-qPCR studies revealed the comparable
expression level between CHIR99021 and PIP-S2-treated
cells and T, GATA4,MESP1 andMSX1 were up regulated
and POU5F1 was down regulated (Figure 5D, bars T,
GATA4, MESP1, MSX1 and POU5F1). Interestingly,
SOX2 down-regulation was more pronounced in PIP-S2-
treated cells than that observed in CHIR99021-treated
cells (Figure 5D, Bars SOX2). To evaluate the efficacy
of PIP-S2 to induce cardiomyocytes, we carried out the
standard protocol with IWP2-treatment as mentioned be-
fore. Immunocytochemistry analysis confirmed the clusters
of TNNT2 (+) cardiomyocytes with PIP-S2 treatment
(Figure 5E, Panel PIP-S2). However, the efficiency was
still lower than CHIR99021-mediated standard protocol
(Figure 5E, Panel CHIR99021). The relatively lower effi-
ciency of cardiomyocyte induction with PIP-S2 treatment
than that with CHIR99021 could be attributed to the
lack of homogeneity of differentiating cells. Nevertheless,
it is important to note here that this observation is also
consistent with the previous reports showing that SOX2
does not specifically inhibit cardiac mesoderm but inhibit
the formation of mesendoderm, including endoderm
and other mesoderm lineages (10,22). Therefore, it is not
straightforward to compare the efficiency of CHIR99021
and PIP-S2. Taken together, the data suggest the potential
of our programmable DNA-binding inhibitor to inhibit
specific transcription factors of interest. Hence, a combi-
natorial approach to target alternate transcription factors
could enhance the efficiency of cardiomyocyte generation.
DISCUSSION
Cardiomyocytes are the critical components that make up
the atria and ventricle of the heart. It is difficult to re-
pair damaged cardiomyocytes as they lose their capacity
for proliferation and regeneration shortly after birth, mak-
ing them unavailable later in life (21). Many cardiomy-
ocytes could in theory be generated from human blastocyst-
derived pluripotent ESCs. Cellular reprogramming strate-
gies like the use of hiPSCs are more promising because
they overcome the problems and ethical dilemmas associ-
ated with human ESCs.
Transgenic approaches such as the introduction of exoge-
nous TFs associated with cardiac cells and gene knockdown
by siRNAs have shown success in modulating target gene
expression directly and in inducing the directed differentia-
tion of hiPSCs into cardiomyocytes (4,10). However, such
transgenic approaches intrinsically have the risk of ‘for-
eign’ genome integration. Alternative strategies such as the
direct transduction of proteins, instead of protein-coding
DNA vectors, could overcome this risk. Accordingly, a re-
cent study demonstrated a bacterial injection-based pro-
tein delivery of Gata4, Mef2c and Tbx5 as a transgene-
free method for the introduction of cardiomyocyte-specific
TFs (36). Nevertheless, time-consuming material prepara-
tion processes and the intrinsic chemically undefined com-
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Figure 5. Cardiomyocyte induction from hiPSCs using PIP-S2. (A) Scheme of the differentiation process. Mesodermal lineage induced by PIP-S2 was
exposed to 5 M of IWP-2 (a Wnt/-catenin inhibitor) for 2 days followed by culture in the medium without any additive. M.C.; medium change. (B)
Spontaneously contracting clusters were counted on day 14. The mean ± SEM of three 90 mm culture dishes is indicated. (C) Immunohistochemistry of
cardiomyocyte markers in differentiated 201B7-hiPSCs withPIP-S2. On day 16, spontaneously contracting clusters were picked up, dissociated, and plated
on cover glasses. Staining was performed on the next day. Scale bars; 50 m. (D) RT–qPCR analysis of 201B7-hiPSCs treated with PIP-S2 + Matrigel
overlay (day 5) and CHIR99021 (day 2). Relative RNA amount (vs undifferentiated 201B7-hiPSCs) is shown in logarithmic scale. Means ± the standard
deviation of the mean (SDM) from multiple culture wells (three each for PIP-S2 treatment and two each for CHIR99021 treatment) in one experiments
are indicated. (E) Immunocytochemistry of cardiomyocyte-specific marker TNNT2 in the differentiated cardiomyocytes by the treatment of PIP-S2 +
Matrigel overlay (day 20) and CHIR99021 (day 15). Scale bars; 200 m.
position of such proteins are still roadblocks to achiev-
ing clinical translation. In this regard, synthetic molecule-
based gene modulation is to be desired because synthetic
molecules could overcome the technical obstacles associ-
ated with the approaches mentioned above. Recently, our
group reported a PIP-based epigenetic activator capable of
activating nervous system genes in hiPSCs (37). Although
the expression of neural genes was demonstrated, the re-
pression of pluripotencymarkers and subsequent differenti-
ation of hiPSCs into a terminal cell type were not achieved.
In the present study, we have characterized PIP-S2 as a
first DNA-binding inhibitor of SOX2, which is an essen-
tial pluripotency TF (Figure 2B and C). Interestingly, PIP-
S2 treatment successfully activated the expression of the
mainmesoderm-specificmarkers includingBRACHYURY,
GSC, MIXL1, MSX1, MESP1 and GATA4 to suggest a
shift in the transcriptional program from a pluripotent to a
cardiac mesodermal state (Figure 3). When incubated with
a Wnt/-catenin signaling inhibitor, the derived mesoderm
could be differentiated successfully into cardiomyocytes,
which is one of the terminal cell types in the mesodermal
lineage. To our knowledge, this work reports the first DNA-
binding synthetic molecule capable of guiding the differen-
tiation of hiPSCs into a particular cell lineage.
Although PIPs are potent DNA-binding molecules
thanks to their unique programmable properties, they have
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not been applied to achieve targeted differentiation of
pluripotent stem cells. In a previous study, the authors
tried inducing differentiation of mouse embryonal carci-
noma (EC) cells and mouse ESCs by the conventional 4–
4 ring module hairpin PIPs targeting the binding sequence
of OCT4, but did not demonstrate remarkable bioactivities
(38). In the present study, we tested a hairpin PIP with a
4–4 ring module and an extended 6–6 ring module, with a
-alanine substitute in one of the rings to reduce the rigid-
ity of the PIP (39,40). As a result, we demonstrated that the
6–6 module PIP (PIP-S2), but not the 4–4 module (PIP-
S1), successfully guided the differentiation of hiPSCs into
mesoderm. The dissociation constant (KD) of a typical 4–4
module PIP is 10−7–10−8 M (41), whereas the 6–6 module
PIP has a KD of 10−8–10−9 M according to previous stud-
ies (42). Importantly, the binding affinity of the 6–6 mod-
ule PIP to the SOX2-target DNA sequence is similar to the
binding affinity of SOX2 whose KD is 5.3 × 10−9 M (43).
Therefore, it is reasonable to assume that the extension of
PIP enhanced its affinity to the target sequence. The exten-
sion might also contribute to enhanced specificity. Because
PIPswith extendedmodules apparently recognize longer se-
quences, they are expected to have higher specificity to tar-
geted sequences in the genome. Therefore, the extension of
a PIP is a significant step for attaining any intended bioac-
tivity.
Unlike the well-studied differentiation routes to achieve
cardiomyocytes, several challenges remain to attain other
cell types from hiPSCs, which include the poor efficiency,
need for transfection of exogenous TFs, and complex cul-
ture techniques (44,45). Over the past decade, loss-/gain-
of-function studies and high-throughput sequencing stud-
ies such as ChIP-seq have identified the critical function of
cell type-specific TFs and their key regulatorymotifs in con-
trolling lineage specification (7–9,46–48). Because PIPs can
be designed to target preferred DNA sequences, the strat-
egy demonstrated in this study could be expanded for ra-
tionally designing PIPs to match corresponding regulatory
sequence motifs and differentiate hiPSCs into any cell type.
Additionally, PIPs are amenable to the conjugation with
other chemical components including epigenetic modula-
tors such as histone deacetylase (HDAC) inhibitors and his-
tone acetyltransferase (HAT) activators, resulting in ‘epige-
netic switches’ which activate selective genes through induc-
tion of histone acetylation (49–53). Combined use of these
‘epigenetic switches’ along with simple PIPs like PIP-S2
as DNA-binding inhibitors will achieve control over more
complex cell fates in our future studies. Overall, this work
serves as a pioneering study for the use of gene-targeting
synthetic molecules in regenerative medicine.
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